Ann: CEO presentation to Broker Meets Biotech - Perth, page-47

Promoting and running a trial costs lots of cash - but that'll drop off.

$6.4m minus $3m, so $3.4m at the end of this quarter.

But if results are good then a deal or takeover is likely to occur.

The company seemed pretty confident. They even tried to get the trial done without the last cap raising. It seemed like as long as they could scrape to the finish line all was ok.

They will be well known to the likes of Smith & Nephew for years. I can imagine that a partner or suitor is already there, just waiting to see those trial figures.